Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 21, 2026 | May 27, 2026 |
| Opy Acquisition Corp. IOHAA · Entity 133726 | Director | October 26, 2021 | October 27, 2021 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | November 20, 2024 | November 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date May 21, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20 | Direct | 123,397 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.
Opy Acquisition Corp. I
Report date October 26, 2021 · Filed October 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
TANDEM DIABETES CARE INC
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 165,190 |
Last balance in matching sequence
After 2024-11-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-11-20 · Sale · Disposed 10,000 · Balance 195,190 F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01 F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Row 2 · 2024-11-21 · Sale · Disposed 30,000 · Balance 165,190 F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63. F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01
F2: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
F3: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
1 source rowRow 1 · 2016-09-28 · Other · Disposed 43,242 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2020-06-30 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 34,500 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2021-07-15 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.74 · Expires 2022-07-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Includes 2,972 unvested shares subject to a restricted stock award.
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2021 Filed Mar 17, 2021 21:52 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 13,044 | $87.85 | $1,145,941.49 |
DisclosureSEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 503,412 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $87.64 to $88.16. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:52 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 135,934 | $87.10 | $11,840,354.36 |
DisclosureSEC source: 0001438133-21-000021 · wf-form4_161601788924421.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 516,456 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $86.64 to $87.64. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:54 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 187,658 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010356 · doc4.xml · derivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from August 27, 2019. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:54 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 51,703 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010356 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 100 | $90.40 | $9,040.00 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 652,390 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,395 | $88.85 | $390,485.20 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 652,490 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F7 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $88.75 to $89.12. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 48,947 | $87.77 | $4,296,107.56 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 656,885 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F6 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $87.42 to $88.10. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 41,158 | $86.68 | $3,567,390.23 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 705,832 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $86.33 to $87.29. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 10,600 | $93.05 | $986,380.88 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 746,990 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $93.05 to $93.09. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,998 | $90.43 | $271,116.04 |
DisclosureSEC source: 0001438133-20-000172 · wf-form4_160825707365239.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 757,590 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $90.40 to $90.54. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 9,150 | $93.00 | $850,950.00 |
DisclosureSEC source: 0001438133-20-000171 · wf-form4_160807024541370.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 760,588 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 13,000 | $95.06 | $1,235,785.20 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 9 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 769,738 F10 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F12 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $95.00 to $95.20. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,850 | $94.22 | $268,522.16 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 8 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 782,738 F10 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F11 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $94.00 to $94.98. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,000 | $91.94 | $183,880.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 7 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 785,588 F9 · kind: The shares were given as a bona fide gift to William D. Snyder and Nicole M.Y. Snyder. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 5,000 | $91.94 | $459,700.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 787,588 F8 · kind: The shares were given as a bona fide gift to Duncan Blickenstaff. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,000 | $91.94 | $183,880.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 792,588 F7 · kind: The shares were given as a bona fide gift to Nicholas Birkland. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 5,000 | $91.94 | $459,700.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 794,588 F6 · kind: The shares were given as a bona fide gift to Randel M. Blickenstaff. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 10,000 | $91.94 | $919,400.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 799,588 F5 · kind: The shares were given as a bona fide gift to Karin Seltmann Trust. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 10,000 | $91.94 | $919,400.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 809,588 F4 · kind: The shares were given as a bona fide gift to Katie Blickenstaff - CS - NN1555. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 5,000 | $91.94 | $459,700.00 |
DisclosureSEC source: 0001438133-20-000166 · wf-form4_160764483798473.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 819,588 F1 · kind: The shares were given as a bona fide gift to Kurt Blickenstaff. F2 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:52 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 25,000 | $97.01 | $2,425,162.50 |
DisclosureSEC source: 0001438133-20-000164 · wf-form4_160703235265078.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 824,588 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $96.50 to $97.33. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 22:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 12,433 | $107.46 | $1,336,111.10 |
DisclosureSEC source: 0001438133-20-000158 · wf-form4_160556643778052.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 849,588 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.00 to $107.84. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 22:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,369 | $105.22 | $459,717.98 |
DisclosureSEC source: 0001438133-20-000158 · wf-form4_160556643778052.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 862,021 F1 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $105.00 to $105.73. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:49 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 6,048 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001438133-20-000157 · wf-form4_160521777197097.xml · derivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,048 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to thirty-three percent (33.33%) of the underlying shares on 05/23/2013, 01/23/2014 and 01/23/2015. F6 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:49 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 25,000 | $100.09 | $2,502,272.50 |
DisclosureSEC source: 0001438133-20-000157 · wf-form4_160521777197097.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 866,390 F3 · shares: Shares sold are from long shares held by the Kim Blickenstaff Revocable Trust, dated April 15, 2010. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $100.00 to $100.82. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:49 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 6,048 | $11.06 | $66,884.83 |
DisclosureSEC source: 0001438133-20-000157 · wf-form4_160521777197097.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 891,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 23,685 | $0.00 Strike: $69.50 | $0.00 |
DisclosureSEC source: 0001438133-20-000131 · wf-form4_159786878189437.xml · derivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 02/16/2017, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter. F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 23,585 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001438133-20-000131 · wf-form4_159786878189437.xml · derivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,625 Underlying: Common Stock · 23,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 02/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 38,250 | $103.49 | $3,958,308.90 |
DisclosureSEC source: 0001438133-20-000131 · wf-form4_159786878189437.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 885,342 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $103.20 to $103.50. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 23,685 | $69.50 | $1,646,107.50 |
DisclosureSEC source: 0001438133-20-000131 · wf-form4_159786878189437.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 923,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 23,585 | $51.50 | $1,214,627.50 |
DisclosureSEC source: 0001438133-20-000131 · wf-form4_159786878189437.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 899,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 11,568 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · derivative · entry 6 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,210 Underlying: Common Stock · 11,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 02/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F7 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,686 | $51.50 | $138,329.00 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · nonDerivative · entry 5 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 876,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 500 | $104.85 | $52,424.00 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · nonDerivative · entry 4 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 873,636 F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $104.79 to $104.87. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,134 | $104.32 | $431,262.60 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · nonDerivative · entry 3 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 874,136 F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $103.78 to $104.72. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 4,248 | $103.34 | $438,983.65 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 878,270 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $102.72 to $103.69. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 8,882 | $51.50 | $457,423.00 |
DisclosureSEC source: 0001438133-20-000130 · wf-form4_159727221114150.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 882,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 200,000 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 22 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vested as to fifty percent (50%) of the underlying shares on 06/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F11 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 11,875 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 21 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,048 Underlying: Common Stock · 11,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 04/23/2014, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter. F11 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionSeries A Warrants · Derivative | 257,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · derivative · entry 20 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Stock · 257,000 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 9,295 | $51.50 | $478,692.50 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 17 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 873,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 75,665 | $18.86 | $1,427,041.90 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 16 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 864,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 4,893 | $11.06 | $54,111.69 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 15 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 788,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 800 | $108.58 | $86,862.24 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 14 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 783,783 F9 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $108.48 to $108.71. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 17,439 | $107.65 | $1,877,236.85 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 13 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 784,583 F8 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.46 to $108.41. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 25,108 | $106.94 | $2,685,170.04 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 12 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 802,022 F7 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $106.46 to $107.45. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 117,897 | $105.86 | $12,480,057.67 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 11 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 827,130 F6 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $105.46 to $106.43. The Reporting Person undertakes to provide the Securitiesand Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 29,927 | $51.50 | $1,541,240.50 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 10 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 945,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 124,335 | $18.86 | $2,344,958.10 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 9 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 915,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 23:58 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 6,982 | $11.06 | $77,213.94 |
DisclosureSEC source: 0001438133-20-000129 · wf-form4_159710392222032.xml · nonDerivative · entry 8 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 790,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.